CORPORATE ACTION NOTICE

TERMINATION NOTICE

BNY MELLON

June 3, 2019

Revised

NOTICE TO HOLDERS OF AMERICAN DEPOSITARY SHARES (“ADSs”) EVIDENCED BY AMERICAN DEPOSITARY RECEIPTS (“ADRs”)

REPRESENTING DEPOSITED ORDINARY SHARES

Azure Health Technology Ltd (f/k/a Moko Social Media Limited)

ONE ADS REPRESENTS FORTY ORDINARY SHARES

CUSIP: 608458204 AND UNDERLYING ISIN: AU0000038879

You were previously notified, as owners and beneficial owners of the above American Depositary Receipts (“ADRs”), that we were to terminate the Deposit Agreement, dated June 26, 2014, among Azure Health Technology Ltd(f/k/a Moko Social Media limited) (“Azure Health Technology”), The Bank of New York Mellon (“BNYM”), as Depositary, and Owners and Holders of American Depositary Shares (the "Deposit Agreement"). As a result, the existing ADR facility was terminated effective at 5:00 PM (Eastern Time) on June 18, 2018.

Currently there is no public trading market for Azure Health Technology ordinary shares as they were suspended from official quotation on the Australian Stock Exchange on January 25, 2017. BNYM’s custodian in Australia has sent notification that transfer, movement, conversion and settlement of the shares is not possible. Accordingly, delivery of those shares upon surrender and cancellation of the ADRs and/or sale of those shares is not practicable or possible.

Holders were previously advised that there is currently no public trading market for the company’s ordinary share. The Depositary will not be able to sell the shares or receive any value for the shares.

Subsequent to the termination, the Company has undergone a name change. As a result effective February 12, 2019, the Company’s name changed to Azure Health Technology Ltd.

BNYM has closed its books for issuance and cancellation.

PLEASE SEE INVESTOR DISCLOSURE ON LAST PAGE.

To learn more about DRs, please contact DRBrokerSolutions@bnymellon.com or visit our website at adrbnymellon.com.

Investor Disclosure

This notice and the information and data provided herein are provided for general informational purposes only. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data. BNY Mellon does not undertake any obligation to update or amend this notice or any information or data, and may change, update or amend this notice or any information or data at any time without prior notice.

BNY Mellon provides no advice, recommendation or endorsement with respect to any company or securities. No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such. We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon this notice or any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

BNY Mellon collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued. From time to time, BNY Mellon may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program. BNY Mellon may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor. BNY Mellon may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. BNY Mellon may execute DR foreign currency transactions itself or through its affiliates; in such cases it acts as principal counterparty and not as agent, advisor, broker or fiduciary. BNY Mellon has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY Mellon earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account. The methodology used by BNY Mellon to determine DR conversion rates is available to registered Owners upon request or at https://www.adrbnymellon.com/us/en/news-and-publications/dr-issuers/asset_upload_file49220_197380.pdf.

BNY Mellon is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle. BNY Mellon is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY MELLON AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.